Wockhardt posts consolidated loss of 102 crore in Q3
Revenues plunge to 699 crore13-02-2023
Q3FY23 Quarterly Result Announced for Wockhardt Ltd.
Pharmaceuticals firm Wockhardt announced Q3FY23 results: Q3FY23: UK business stood at Rs 223 crore in Q3FY23. UK business contributed about 32% of global revenue. India Business stood at Rs 175 crore compared to Rs 158 crore in Q3FY22, registering a growth of 11%. India Business contributed 25% of the global revenue. Emerging markets business of the company stood at Rs 148 crore in Q3FY23 compared to Rs 117 crore in Q2FY23, registering a growth of 27%. Emerging markets business contributed about 21% of the global revenue. Irish business stood at Rs 40 crore in Q3FY23 compared to Rs 38 crore in Q2FY23, showing a growth of 4%. US business stood at Rs 91 crore in Q3FY23. US business contributed 13% of the global revenue. Research and development expenditure during the quarter was at Rs 40 crore (6% to sales) and including capital expenditure was at 10.3% to sales. 9MFY23: UK business stood at Rs 645 crore in 9MFY23. UK business contributed about 33% of global revenue. India business stood at Rs 483 crore. India business contributed 25% of the global revenue. Emerging markets business of the company stood at Rs 382 crore in 9MFY23. Emerging markets business contributed about 19% of the global revenue. Irish business stood at Rs 115 crore in 9MFY23. US business stood at Rs 253 crore in 9MFY23. US business contributed 13% of the global revenue. Research and development expenditure during the period was at Rs 115 crore (6% to sales) and including capital expenditure was at 10.9% to sales. Result PDF13-02-2023
WOCKHARDT LTD. - 532300 - Outcome Of The Board Meeting
Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'); we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 13th February, 2023, inter-alia, have approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 31st December, 2022; and Limited Review Report thereon issued by B S R & Co. LLP., Statutory Auditors of the Company; Pursuant to Regulations 30 and 33 of Listing Regulations read with Schedule III of Listing Regulations, we enclose herewith the following: a. Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 31st December, 2022; and Limited Review Report issued by B S R & Co. LLP., Statutory Auditors of the Company (enclosed as Annexure I). b. A copy of the Press Release proposed to be issued in respect of the said Financial Results (enclosed as Annexure II).13-02-2023
WOCKHARDT LTD. - 532300 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Wockhardt Limited: Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')08-02-2023
WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
We wish to inform you that the Share Allotment Committee of the Board of Directors of the Company has allotted 28,170 equity shares of face value of Rs.5/- each on 6th February, 2023, pursuant to exercise of stock options under Employee Stock Options Scheme - 2011 of the Company. In view of the above, the paid-up equity share capital of the Company will increase from Rs.72,03,00,765/- (14,40,60,153 equity shares of Rs. 5/- each) to Rs.72,04,41,615/- (14,40,88,323 equity shares of Rs. 5/- each). The Equity Shares as allotted above shall rank pari-passu with the existing Equity Shares of the Company and shall be entitled to all dividends and corporate benefits, if any, declared by the Company after the allotment.06-02-2023
WOCKHARDT LTD. - 532300 - Board Meeting Intimation for Considering And Approving The Un-Audited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended 31St December, 2022.
WOCKHARDT LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023 ,inter alia, to consider and approve the Un-Audited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 31st December, 2022.03-02-2023
WOCKHARDT LTD. - 532300 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Certificate18-01-2023
WOCKHARDT LTD. - 532300 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBICAP Trustee Company Ltd16-01-2023
WOCKHARDT LTD. - 532300 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate in terms of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended on 31st December, 2022.12-01-2023
WOCKHARDT LTD. - 532300 - Closure of Trading Window
Closure of Trading window for declaration of financials for the quarter and nine months ended 31st December, 202226-12-2022